HPV vaccine hesitancy among French clinicians means low uptake among MSM

  • Petit B & al.
  • Vaccine
  • 24 Feb 2020

  • curated by Liz Scherer
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • HPV vaccine coverage among French men who have sex with men (MSM) is low and associated with infrequent physician-driven uptake.

Why this matters

  • Discuss, offer HPV vaccine uptake in MSM, especially those under age 27 years.
  • Address vaccine hesitancy using data demonstrating direct link between vaccination and cancer prevention/reduction.

Key results

  • 2094 MSM; mean age, 35.4±11 years (24.3% represented HPV vaccine targeted age class).
  • Overall, using a 1-10 scale, participants scored items as follows:
    • Vaccination: 10 (interquartile range [IQR], 8-10); 
    • Vaccine usefulness: 10 (IQR, 9-10; Rho=0.848; P<.001>
    • Vaccine harmfulness: 2 (IQR, 2-5).
      • Positive correlation seen for vaccine usefulness in favor of vaccination (Rho=0.848; P<.001>
  • MSM taking preexposure prophylaxis (PrEP) had higher perception of vaccine utility (P<.001>
  • 16.5% (345) of participants with ≥1 physician vs 9.9% (171, 9.9% in target age class) with a family physician had HPV vaccination offered to them. 
  • 17.9% (90/541) of participants in target age class received ≥1 vaccine dose; 52.2% (21/40) were using PrEP.
  • 45.7% (839) would accept HPV vaccination if offered.

Study design

  • Online survey to determine HPV vaccine coverage among French MSM, including physician recommendations, vaccine perceptions, October 2018-January 2019.
  • Funding: None disclosed.

Limitations

  • Limited generalizability.
  • Self-report bias.